Javascript Disabled

This site requires Javascript in order to function properly. Please enable it in your browser's settings.

CDK 4/6 Dual Inhibitor Derived from Shapiro GI1; Ibrahim N and Haluska FG.2

Target

Many human tumors acquire alterations, which can lead to the activation of cyclin-dependent kinases (CDKs)—CDK4 and CDK6. These alterations include mutations that directly activate CDK4/6, gene amplifications, which increase expression of various protein activators such as cyclin D, as well as genetic losses, which reduce expression of protein inhibitors such as p16. These various mechanisms as well as loss of retinoblastoma (Rb) can lead to an enhanced proliferative potential by decreasing dependency on external growth factors and mitogenic signaling pathways, which are required to stimulate growth under normal conditions.3,4

Molecule

Abemaciclib (LY2835219) has been shown in vitro to be a selective ATP-competitive inhibitor of CDK4/6 kinase activity that prevents the phosphorylation and subsequent inactivation of the Rb tumor suppressor protein, thereby inducing G1 cell cycle arrest and inhibition of cell proliferation.5,6

Clinical Development

Abemaciclib is being investigated in phase I clinical trials and in clinical trials in patients with mantle cell lymphoma, non-small cell lung cancer, and breast cancer.

CDK 4/6 Dual Inhibitor

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without LY2835219, a CDK 4/6 Inhibitor, for Women With Hormone-Receptor-Positive (HR+), HER2-Negative Locally Advanced or Metastatic Breast Cancer (MONARCH 2)

Key Inclusion Criteria

  • Presence of either locally advanced disease not amenable to curative treatment by surgery or metastatic disease
  • Postmenopausal status due to either surgical/natural menopause or ovarian suppression with a gonadotropin-releasing hormone agonist (initiated ≥28 days prior to randomization)
  • Measurable disease or nonmeasurable bone only disease (according to Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1)
  • Adequate organ function
  • ECOG performance status of ≤1
  • Discontinuation of prior cancer therapies for at least 21 or 14 days for myelosuppressive or nonmyelosuppressive agents, respectively, and recovered from acute effects of therapy

Key Exclusion Criteria

  • Visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis
  • Central nervous system metastases
  • Prior treatment with chemotherapy (except for neoadjuvant/adjuvant chemotherapy), fulvestrant, everolimus, or any CDK 4/6 inhibitor

Please visit www.clinicaltrials.gov for more information on this clinical trial [NCT02107703].

CDK 4/6 Dual Inhibitor

A Randomized Phase 3 Study of LY2835219 Plus Best Supportive Care vs Erlotinib Plus Best Supportive Care in Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy (JUNIPER)

Key Inclusion Criteria

  • The participants must have confirmed diagnosis of stage IV NSCLC according to the American Joint Committee on Cancer Staging Handbook
  • Determined to have detectable mutations in codons 12 or 13 of the KRAS oncogene by an investigational assay at the central study laboratory
  • The participant must have progressed after platinum-based chemotherapy (with or without maintenance therapy) AND have received one other prior chemotherapy for advanced and/or metastatic disease OR is judged by the physician as ineligible for further standard second-line chemotherapy
  • Has measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
  • ECOG performance status of 0 to 1
  • Has discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and investigational therapy) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug

Key Exclusion Criteria

  • Has received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agent, respectively
  • Has a personal history of any of the following conditions: presyncope or syncope of either unexplained or cardiovascular etiology, ventricular arrhythmia (including but not limited to ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest
  • Has the presence of unstable central nervous system (CNS) metastasis. Histories of CNS metastasis or stable CNS metastases are allowed (no longer requiring active therapy such as steroid medications). Participants with a history of CNS metastases must have a brain scan (for example, magnetic resonance imaging) within 28 days of randomization to document stability, even if there have been no changes in symptoms

Please visit www.clinicaltrials.gov for more information on this clinical trial [NCT02152631].

CDK 4/6 Dual Inhibitor

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women With Hormone-Receptor-Positive (HR+), HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer With No Prior Systemic Therapy in This Disease Setting (MONARCH 3)

Key Inclusion Criteria

  • Has a diagnosis of HR+, HER2-negative breast cancer
  • Has locoregionally recurrent disease not amenable to resection or radiation therapy with curative intent or metastatic disease
  • Has postmenopausal status
  • Has measurable disease or nonmeasurable bone only disease (according to Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1)
  • ECOG performance status of ≥1
  • Has discontinued previous localized radiotherapy for palliative purposes or for lytic lesions at risk of fracture at least 2 weeks prior to randomization and recovered from the acute effects of therapy (until the toxicity resolves to either baseline or at least grade 1) except for residual alopecia or peripheral neuropathy

Key Exclusion Criteria

  • Has visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis
  • Has clinical evidence or a history of central nervous system metastasis
  • Currently receiving or has previously received chemotherapy or endocrine therapy for locoregionally recurrent or metastatic breast cancer
  • Has received prior (neo)adjuvant endocrine therapy (eg, anti-estrogens or aromatase inhibitors) with a disease-free interval ≤12 months from completion of treatment
  • Prior treatment with everolimus or any CDK4/6 inhibitor

Please visit www.clinicaltrials.gov for more information on this clinical trial.

CDK 4/6 Dual Inhibitor

A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone-Receptor-Positive (HR+), HER2-Negative Metastatic Breast Cancer (MONARCH 1)

Key Inclusion Criteria

  • Diagnosis of HR+, HER2-negative breast cancer that expresses, by immunohistochemistry, at least one of the hormone receptors (estrogen receptor [ER] or progesterone receptor [PR]) and does not demonstrate overexpression of HER2
  • Has recurrent, locally advanced, unresectable or metastatic breast cancer with disease progression following anti-estrogen therapy
  • Has had prior treatment with at least 2 chemotherapy regimens:
    -
    At least 1, but no more than 2, of these regimens must have been administered in the metastatic setting
    -
    At least 1 of these regimens must have contained a taxane
  • ECOG performance status of 0 to 1
  • Has discontinued all previous therapies for cancer for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug and recovered from the acute effects of therapy
  • Has the presence of measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

Key Exclusion Criteria

  • Has either a history of central nervous system (CNS) metastasis or evidence of CNS metastasis on the magnetic resonance imaging of brain obtained at baseline
  • Has received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agent, respectively. Patients are not eligible if they have received prior therapy with another CDK 4/6 inhibitor
  • Has had major surgery within 14 days of the initial dose of study drug
  • Has a history of any other cancer (except nonmelanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission with no therapy for a minimum of 3 years
  • Has initiated approved bisphosphonates or approved RANK ligand (RANK-L) targeted agents (for example, denosumab) ≤28 days prior to day 1 of cycle 1

Please visit www.clinicaltrials.gov for more information on this clinical trial [NCT02102490].

CDK 4/6 Dual Inhibitor

A Phase 1b Study of LY2835219 in Combination With Endocrine Therapies for Patients With Hormone-Receptor-Positive (HR+), HER2-Negative, Metastatic Breast Cancer (mBC)

Key Inclusion Criteria

  • Diagnosis of HR+, HER2-negative breast cancer that expresses, by immunohistochemistry, at least one of the hormone receptors (estrogen receptor [ER] or progesterone receptor [PR])
  • For parts A and B, the patient must not have received prior systemic endocrine therapy for metastatic disease except for ongoing therapy with letrozole (part A) or anastrozole (part B)
  • For part C, the patient may have received prior systemic endocrine therapy for metastatic disease and may be receiving ongoing therapy with tamoxifen
  • For parts D and E, the patient must have received prior systemic endocrine therapy with at least one nonsteroidal aromatase inhibitor (anastrozole or letrozole) for metastatic disease and may be receiving ongoing therapy with exemestane (part D) or exemestane + everolimus (part E)
  • Female ≥18 years of age who must have either postmenopausal status or premenopausal status if continuing or beginning ovarian suppression with a luteinizing hormone-releasing hormone (LHRH) agonist
  • ECOG performance status of ≤1
  • Has discontinued all previous therapies for breast cancer, except for ongoing endocrine therapy, for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug(s) and recovered from the acute effects of therapy
  • Has either measurable or nonmeasurable disease but evaluable bone disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
  • Has adequate organ function

Key Exclusion Criteria

  • Has mBC with visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis
  • Has received prior systemic chemotherapy for metastatic disease
  • Intolerant of the standard endocrine therapy drug(s) administered in a specific part of the study
  • Has initiated bisphosphonates or approved RANK ligand (RANK-L) targeted agents (for example, denosumab) ≤28 days prior to day 1 of cycle 1
  • Has central nervous system metastasis without prior radiotherapy or either radiotherapy or development of neurological changes ≤14 days prior to receiving study treatment

Please visit www.clinicaltrials.gov for more information on this clinical trial [NCT02057133].

CDK 4/6 Dual Inhibitor

A Phase 1b Study of LY2835219 in Combination With Multiple Single-Agent Options for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)

Key Inclusion Criteria

  • For all study parts: The patient must have stage IV NSCLC. All patients with nonsquamous NSCLC with EGFR-activating mutations or anaplastic lymphoma kinase alterations should have received appropriate tyrosine kinase inhibitor therapy prior to enrollment
    -
    Part A: Nonsquamous subtypes only. The patient must have received 1-3 prior therapies, including 1 platinum-based chemotherapy for advanced/metastatic NSCLC. Patients who have received pemetrexed as first-line or maintenance therapy must be ≥3 months after treatment for determining eligibility
    -
    Part B: Any subtype. The patient must have received 1-3 prior therapies for advanced/metastatic NSCLC
    -
    Part C: Any subtype. The patient must have received 2-3 prior therapies for advanced/metastatic NSCLC
    -
    Part D (US only): Any subtype. The patient must have received 2-3 prior therapies for advanced/ metastatic NSCLC. The patient must not have received prior treatment with a MEK inhibitor
  • Has the presence of either measurable or nonmeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
  • ECOG performance status of ≤1
  • Has discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and investigational therapy) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug and recovered from the acute effects of therapy (treatment-related toxicity resolved to baseline) except for residual alopecia
  • Males and females with reproductive potential must agree to use medically approved contraceptive precautions during the trial and for 3 months following the last dose of study drug. Females with childbearing potential must have a negative serum pregnancy test within 7 days of the first dose of study drug

Key Exclusion Criteria

  • All study parts: Has a history of syncope of unexplained or cardiovascular etiology, or cardiac arrest. Subjects with controlled atrial fibrillation for >30 days prior to study treatment are eligible
  • Parts A, B, and D only: Has central nervous system (CNS) metastasis with development of associated neurological changes 14 days prior to receiving study drug. Patients may be receiving a stable dose of corticosteroids. Screening of asymptomatic patients without history of CNS metastasis is not required. Patients with untreated CNS metastases are ineligible
  • Part C:
    -
    History of cardiac disease, coronary artery disease, heart failure, or syncope. History or evidence of CNS metastases. Radiographic screening of all patients without history of CNS metastasis is required
    -
    Radiologically documented evidence of major blood vessel invasion or encasement by cancer or radiographic evidence of intratumor cavitation, regardless of tumor histology
    -
    Patients with uncontrolled thromboembolic or hemorrhagic disorders
    -
    Patients receiving chronic daily treatment with aspirin ≥325 mg/day or other known inhibitors of platelet function
    -
    Patients with a history of gross hemoptysis (defined as bright red blood of ≥1/2 teaspoon) within 2 months of study entry
    -
    Patients with nonhealing wounds, ulcers, or bone fractures, or undergone a major surgery within 28 days prior to study entry
  • Part D: History of interstitial lung disease, cardiac disease, coronary artery disease, or risk of ocular disease, such as retinal vein occlusion

Please visit www.clinicaltrials.gov for more information on this clinical trial [NCT02079636].

[NCT01394016]    Early Development    A Phase 1 Study of LY2835219 in Participants With Advanced Cancer

[NCT02014129]    Early Development    A Study of LY2835219 in Japanese Participants With Advanced Cancer

[NCT01739309]    Hematologic Cancer    Study of LY2835219 for Mantle Cell Lymphoma